Rhumbline Advisers Has $21.09 Million Position in Hologic, Inc. (HOLX)

Rhumbline Advisers increased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 4.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 574,802 shares of the medical equipment provider’s stock after purchasing an additional 26,337 shares during the quarter. Rhumbline Advisers owned 0.20% of Hologic worth $21,089,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Hall Laurie J Trustee raised its holdings in Hologic by 10.2% in the 2nd quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after purchasing an additional 225 shares during the period. Commonwealth Bank of Australia raised its holdings in Hologic by 31.0% in the 2nd quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock worth $114,000 after purchasing an additional 600 shares during the period. MPS Loria Financial Planners LLC acquired a new position in Hologic in the 2nd quarter worth about $191,000. National Asset Management Inc. acquired a new position in Hologic in the 2nd quarter worth about $203,000. Finally, Beck Mack & Oliver LLC acquired a new position in Hologic in the 2nd quarter worth about $209,000. 97.72% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://stocknewstimes.com/2017/11/20/rhumbline-advisers-has-21-09-million-position-in-hologic-inc-holx.html.

A number of equities analysts have commented on the company. Royal Bank Of Canada reduced their target price on Hologic from $50.00 to $45.00 and set a “sector perform” rating for the company in a report on Thursday, August 3rd. BidaskClub cut Hologic from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Zacks Investment Research raised Hologic from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Barclays PLC reduced their target price on Hologic from $53.00 to $51.00 and set an “overweight” rating for the company in a report on Thursday, August 3rd. Finally, Needham & Company LLC reissued a “buy” rating and set a $50.00 target price on shares of Hologic in a report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $47.54.

In related news, Director Lawrence M. Levy sold 7,138 shares of the stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $37.38, for a total value of $266,818.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Lawrence M. Levy sold 7,139 shares of the stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $39.04, for a total value of $278,706.56. The disclosure for this sale can be found here. In the last ninety days, insiders sold 34,949 shares of company stock valued at $1,345,220. Insiders own 0.79% of the company’s stock.

Shares of Hologic, Inc. (NASDAQ HOLX) opened at $39.96 on Monday. Hologic, Inc. has a fifty-two week low of $35.76 and a fifty-two week high of $46.80. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.79 and a quick ratio of 0.61. The company has a market capitalization of $11,519.41, a P/E ratio of 19.78, a P/E/G ratio of 1.93 and a beta of 0.93.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 EPS for the quarter, beating the consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The firm had revenue of $802.90 million during the quarter, compared to analysts’ expectations of $792.54 million. During the same quarter last year, the firm earned $0.52 earnings per share. The business’s revenue for the quarter was up 10.5% on a year-over-year basis. research analysts forecast that Hologic, Inc. will post 2.12 EPS for the current year.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply